| abstract |
1.- A liquid formulation comprising ribavirin; a buffering system, the pH of the liquid formulation being in the order of from about 4.8 to about 5.3; at least one pharmaceutically acceptable sweetening agent; and at least one agent that increases the pharmaceutically acceptable viscosity. 2.- The liquid formulation according to claim 1, wherein the buffering system comprises sodium citrate dihydrate and anhydrous citric acid. 3.- The liquid formulation of according to claim 2, in which the sodium citrate dihydrate is present in a concentration of about 5 grams / liter and the anhydrous citric acid is present in a concentration of about 2 grams / liter. 4. The liquid formulation of according to claim 1, in which ribavirin is present in a concentration of from about 20 to about 65 grams / liter. 5. The liquid formulation according to claim 4, in which ribavirin is present in a concentration of about 40 grams / liter. 6. The liquid formulation according to claim 1, in which at least two sweetening agents are present. pharmaceutically acceptable. |